Aegerion’s Lomitapide Gets Standard Review For Rare Genetic Cholesterol Disease
This article was originally published in The Pink Sheet Daily
Aegerion is preparing for an advisory committee meeting after submitting its LDL-C lowering oral drug lomitapide to FDA for patients with homozygous familial hypercholesterolemia. The NDA was submitted ahead of that for Isis/Genzyme’s injectable competitor, mipomersen.
You may also be interested in...
FDA will be using an upcoming advisory panel review of Aegerion Pharmaceuticals Inc.’s lomitapide to see if there is still support for traditional lipid endpoints in clinical trials of cholesterol drugs.
Alexion’s “hotly contested” purchase of Enobia last December didn’t get much attention, but it marked a watershed year for rare disease drug deals. Will high drug prices, skittish regulators and a gold-rush push by Big Pharma start to sour the sector?
Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.